PUBLIC COMPANY
save$SMMTSummit Therapeutics Inc.
$SMMT16.75+0.39%Miami, FL, USupdated 1d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1pre_registration
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
- phase3Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- phase3Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- phase3Phase III Study of AK112 for NSCLC Patients
- phase3Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
- phase3Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
🐶 Hiring Signal
next earnings Oct 19, 2026
News
- Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestonePlus news about Regeneron. Summit Therapeutics to test cancer drug with Datroway: The biotech agreed to partner with AstraZeneca and Daiichi Sankyo on a clinical trial collaboration, testing its Tr…endpoints · 2d ago
- STAT+: HHS announces new efforts to speed up, expand clinical trials with AIFederal health officials want to speed up clinical research to compete with countries like China.stat · 4d ago
- STAT+: Three biotech updates, including accusations of theft and and a new lobbying leaderBeam Therapeutics has filed a lawsuit alleging one of its former scientists stole intellectual property and used it to co-found a Chinese company that recently made a deal with prominent VC…stat · 4d ago
- AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a rollSummit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene t…biospace · 4d ago
- Opinion: America’s biotech race with China must be won at home“The surest way to secure our biotech lead is to build up our own capabilities,” write Gary Locke and Patrick McHenry.stat · 4d ago
- STAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual propertyThe gene-editing company Beam Therapeutics is alleging that one of its scientists stole intellectual property and used it to co-found a Chinese company that made a deal with VC firms.stat · 5d ago
- STAT+: Overton won’t get a vote before midtermsHealth department nominees await Senate votes, and we map out what the elections mean for healthy policy.stat · 5d ago
- STAT+: AstraZeneca invests $2 billion in Summit TherapeuticsAstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.stat · 5d ago
- Summit snags $2B investment from AstraZeneca, clearing financial overhangThe all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights.biospace · 5d ago
- AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug pushThe equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.biopharma_dive · 5d ago
Data sources
last refreshed 44m ago
Found something off?
comments(0)
5-min edit window · permanent after that